Literature DB >> 15875906

Establishment and partial characterization of five malignant glioma cell lines.

Lei Zhang1, Tetsu Yamane, Eiji Satoh, Kenichi Amagasaki, Tomoyuki Kawataki, Takayuki Asahara, Koro Furuya, Hideaki Nukui, Hirofumi Naganuma.   

Abstract

Five malignant glioma cell lines (YMG1, 2, 3, 4, and 5) were established from surgical specimens obtained from patients with glioblastoma or anaplastic astrocytoma, and these lines were partially characterized. Three glioma cell lines (YMG1, 3, and 5) were weakly positive for GFAP by Western blot analysis and two cell lines were negative. S-100 protein was positive in all glioma cell lines. The expression of p53, p16, p15, cyclin-dependent kinase 4 (CDK4), and EGF receptor (EGFR) proteins was examined by Western blotting. YMG1 and 2 cell lines showed accumulation of p53 protein and loss of p16 and p15 expression. YMG3 and 4 showed accumulation of p53 protein and expression of p16 and p15 proteins. YMG5 revealed weak expression of p53 protein, suggesting wild-type p53, and loss of p16 and p15 expression. All cell lines expressed various levels of CDK4 protein. YMG1, 2, and 3 showed higher EGFR protein expression and YMG4 and 5 showed lower EGFR expression compared to U251 glioblastoma cells, which express high levels of EGFR. Fluorescence in situ hybridization analysis for EGFR gene expression did not show any amplification in the glioma cell lines. Immunohistochemical studies revealed that the patterns of p53 and EGFR expressions in the original tumor tissues were mostly correlated with those in the malignant glioma cell lines. These results suggest that the characteristics of p53 and EGFR expression in the malignant glioma cell lines were passed over from the original tumor tissues. These newly established malignant glioma cell lines can be used for further analysis of the mechanisms of tumor growth and progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15875906     DOI: 10.1111/j.1440-1789.2005.00601.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  4 in total

1.  Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas: participation of nuclear factor-kappaB in upregulation of syndecan-1 expression.

Authors:  Arata Watanabe; Tadashi Mabuchi; Eiji Satoh; Koro Furuya; Lei Zhang; Shuichiro Maeda; Hirofumi Naganuma
Journal:  J Neurooncol       Date:  2006-03       Impact factor: 4.130

2.  Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.

Authors:  Mehmet Taspinar; Seda Ilgaz; Mevci Ozdemir; Tulin Ozkan; Derya Oztuna; Hande Canpinar; Juan A Rey; Asuman Sunguroğlu; Javier S Castresana; Hasan Caglar Ugur
Journal:  Tumour Biol       Date:  2013-03-22

3.  Targeted antiepidermal growth factor receptor (cetuximab) immunoliposomes enhance cellular uptake in vitro and exhibit increased accumulation in an intracranial model of glioblastoma multiforme.

Authors:  Joachim Høg Mortensen; Maria Jeppesen; Linda Pilgaard; Ralf Agger; Meg Duroux; Vladimir Zachar; Torben Moos
Journal:  J Drug Deliv       Date:  2013-09-23

4.  Immunohistochemical Characterization and Sensitivity to Human Adenovirus Serotypes 3, 5, and 11p of New Cell Lines Derived from Human Diffuse Grade II to IV Gliomas.

Authors:  Minna Niittykoski; Mikael von Und Zu Fraunberg; Miika Martikainen; Tuomas Rauramaa; Arto Immonen; Susanna Koponen; Ville Leinonen; Markus Vähä-Koskela; Qiwei Zhang; Florian Kühnel; Ya-Fang Mei; Seppo Ylä-Herttuala; Juha E Jääskeläinen; Ari Hinkkanen
Journal:  Transl Oncol       Date:  2017-08-04       Impact factor: 4.243

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.